1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
2. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–1549.
3. Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(2):132–141.
4. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(2):96–104.
5. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Gastroenterology. 2008;134(5): 1570–1595.
6. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627–637.
7. Council of the European Union. Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC). Official Journal of the European Union. 2003;327:34–38. Luxembourg, Luxembourg: Council of the European Union. (
8. Ontario Ministry of Health and Long-term Care. Colon cancer check. Toronto, Ontario, Canada: Ontario Ministry of Health and Long-term Care; 2008. (
9. von Karsa L, Anttila A, Ronco G, et al. Cancer Screening in the European Union. Report on the Implementation of the Council Recommendation on Cancer Screening. Lyon, France: International Agency for Research on Cancer; 2008.
10. Houston M. Ireland’s recommended colorectal cancer screening programme will not get extra government funding. BMJ. 2009;338:b2551. doi: 10.1136/bmj.b2551.
11. Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen. 2006; 13(suppl 1):S6–S7.
12. van Veen W, Mali WP. Colorectal cancer screening: advice from the Health Council of the Netherlands [in Dutch] (discussion). Ned Tijdschr Geneeskd. 2009;153:A1441.
13. Young GP. Population-based screening for colorectal cancer: Australian research and implementation. J Gastroenterol Hepatol. 2009;24(suppl 3):S33–S42.
14. Pignone M, Saha S, Hoerger T, et al. Challenges in systematic reviews of economic analyses. Ann Intern Med. 2005;142(12 pt 2):1073–1079.
15. International Monetary Fund. IMF exchange rates query tool. Washington, DC: International Monetary Fund; 2010. (
16. US Department of Labor. Bureau of Labor Statistics. Consumer Price Index - all urban consumers. Item: medical care. Washington, DC: US Department of Labor, Bureau of Labor Statistics; 2010. (
17. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer. 2009;124(5):1161–1168.
18. Wagner J, Tunis S, Brown M, et al. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rozen P, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. London, United Kingdom: Saunders; 1995:321–356.
19. Pickhardt PJ, Hassan C, Laghi A, et al. Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions. Cancer. 2007;109(11):2213–2221.
20. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126(5): 1270–1279.
21. Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomarkers Prev. 2009;18(7): 1971–1978.
22. Zauber A, Knudsen AB, Rutter CM, et al. Cost-effectiveness of CT colonography to screen for colorectal cancer: report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET); 2009. (http:// www.cms.hhs.gov/mcd/viewtechassess.asp?id1⁄4220). (Accessed October 29, 2010).
23. Vijan S, Hwang I, Inadomi J, et al. The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol. 2007;102(2):380–390.
24. Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95(7):1800–1811.
25. Whynes DK, Neilson AR, Walker AR, et al. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ. 1998;7(1):21–29.
26. Tappenden P, Chilcott J, Eggington S, et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56(5):677–684.
27. Stone CA, Carter RC, Vos T, et al. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial 
28. Gyrd-Hansen D, Søgaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Econ. 1998; 7(1):9–20.
29. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol. 1997;36(suppl 9):1–60.
30. Norum J. Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy. Ann Oncol. 1998;9(6):613–618.
31. Salkeld G, Young G, Irwig L, et al. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia. Aust N Z J Public Health. 1996;20(2): 138–143.
32. Shimbo T, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care. 1994;10(3):359–375.
33. Berchi C, Bouvier V, R  ́aud JM, et al. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2004;13(3):227–238.
34. Flanagan WM, Le Petit C, Berthelot JM, et al. Potential impact of population-based colorectal cancer screening in Canada. Chronic Dis Can. 2003;24(4):81–88.
35. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284(15):1954–1961.
36. Helm JF, Russo MW, Biddle AK, et al. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95(11): 3250–3258.
37. Khandker RK, Dulski JD, Kilpatrick JB, et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care. 2000;16(3):799–810.
38. Lejeune C, Arveux P, Dancourt V, et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care. 2004;20(4):434–439.
39. Leshno M, Halpern Z, Arber N. Cost-effectiveness of colorectal cancer screening in the average risk population. Health Care Manag Sci. 2003;6(3):165–174.
40. O’Leary BA, Olynyk JK, Neville AM, et al. Cost-effectiveness of colorectal cancer screening: comparison of community- based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol. 2004;19(1):38–47.
41. Sonnenberg A, Delc ` F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med. 2000;133(8):573–584.
42. Steele RJ, Gnauck R, Hrcka R, et al. Methods and economic considerations: group 1 report. ESGE/UEGF colorectal cancer—public awareness campaign. The public/professional interface workshop: Oslo, Norway, June 20–22, 2003. Fulfillment corporate. Endoscopy. 2004;36(4):349–353.
43. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen. 2007;14(4):191–199.
44. Hassan C, Zullo A, Laghi A, et al. Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy. Dig Liver Dis. 2007;39(3):242–250.
45. Macafee DA, Waller M, Whynes DK, et al. Population screening for colorectal cancer: the implications of an ageing population. Br J Cancer. 2008;99(12):1991–2000.
46. Tsoi KK, Ng SS, Leung MC, et al. Cost-effectiveness analysis on screening for colorectal neoplasm and management of 
47. Wu GH, Wang YM, Yen AM, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer. 2006;6:136. doi: 10.1186/1471-2407-6-136.
48. Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 2001;111(8):593–601.
49. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther. 2008; 27(8):697–712.
50. Li S, Wang H, Hu J, et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006;118(12):3078–3083.
51. van Ballegooijen M, Habbema JD, Boer R, et al. A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. Report PUB: Agency Healthcare Res Qual. 2003:1–59.
52. Zauber A, Lansdorp-Vogelaar I, Wilschut J, et al. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007. (https:// www.cms.hhs.gov/mcd/viewtechassess.asp? where1⁄4index&tid1⁄452). (Accessed October 29, 2010).
53. Ladabaum U, Song K, Fendrick AM. Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? Clin Gastroenterol Hepatol. 2004;2(7):554–563.
54. Sonnenberg A, Delc ` F, Bauerfeind P. Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Am J Gastroenterol. 1999;94(8):2268–2274.
55. Hassan C, Zullo A, Winn S, et al. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer. Endoscopy. 2008;40(5):414–421.
56. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–1258.
57. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–1633.
58. Pignone M, Russell L, Wagner J. Economic models of colorectal cancer screening in average-risk adults: workshop summary. Washington, DC: Institute of Medicine and National Research Council of the National Academies; 2005. (
59. Statistical Research & Applications Branch; National Cancer Institute. Cancer intervention and surveillance modeling network. Bethesda, MD: Statistical Research & Applications Branch, National Cancer Institute; 2008. (
60. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659–669.
61. Harris R. Speaking for the evidence: colonoscopy vs computed tomographic colonography. J Natl Cancer Inst. 2010;102(16): 1212–1214.
62. Colorectal cancer screening tests: conditions for and limitations on coverage. In: 62 Federal Register 59100. October 31, 1997, as amended at 66 FR 55329, November 1, 2001; 67 FR 80040, December 31, 2002.
63. Leddin D, Bridges RJ, Morgan DG, et al. Survey of access to gastroenterology in Canada: the SAGE wait times program. Can J Gastroenterol. 2010;24(1):20–25.
64. Chivers K, Basnyat P, Taffinder N. The impact of national guidelines on the waiting list for colonoscopy: a quantitative clinical audit. Colorectal Dis. 2010;12(7):632–639.
65. Yeoman A, Parry S. A survey of colonoscopy capacity in New Zealand’s public hospitals. N Z Med J. 2007;120(1258): U2632. (PMID: 17653250).
66. Price J, Campbell C, Sells J, et al. Impact of UK Colorectal Cancer Screening Pilot on hospital diagnostic services. J Public Health (Oxf). 2005;27(3):246–253.
67. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62–68.
68. Boudreau DM, Luce CL, Ludman E, et al. Concordance of population-based estimates of mammography screening. Prev Med. 2007;45(4):262–266.
69. Shapiro JA, Seeff LC, Thompson TD, et al. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(7): 1623–1630.
70. Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2010;105(3):682–690.
71. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441–450, W481.
72. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103(11):2862–2870.